

**Amendments to the Claims**

This listing of claims will replace all prior versions and listings of claims in the application:

**Listing of Claims:**

1(Original). A purified polypeptide, comprising an amino acid sequence selected from the group consisting of:

(a) SEQ ID NO:6; where amino acid residue 73, as represented by Xaa, is Ile or Thr;

(b) a contiguous fragment of SEQ ID NO:6, which fragment induces interferon- $\gamma$  production in immunocompetent human cells; and

(c) a variant of (a) or (b) differing therefrom by replacement of one amino acid residue, which variant induces interferon- $\gamma$  production in immunocompetent human cells.

2(Original). The purified polypeptide of claim 1, which has a molecular weight of about  $18,500 \pm 3,000$  daltons on sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and an isoelectric point of about  $4.9 \pm 1.0$  on chromatofocusing.

Claim 3 (Cancelled)

4(Original). The purified polypeptide of claim 1, which comprises the amino acid sequence of a contiguous fragment

Appln. No. 09/716,356  
Amd. dated January 20, 2006  
Reply to Office Action of September 21, 2005

of SEQ ID NO:6, where amino acid residue 73, as represented by Xaa, is Ile or Thr, which fragment induces interferon- $\gamma$  production in immunocompetent human cells.

5(Original). The purified polypeptide of claim 1, which comprises a variant of (a) or (b) differing therefrom by replacement of one amino acid residue, which variant induces interferon- $\gamma$  production in immunocompetent cells.

6(Original). A pharmaceutical composition, comprising the polypeptide of claim 1 as an active ingredient and a pharmaceutically-acceptable carrier.

7(Original). The pharmaceutical composition of claim 6, further comprising interleukin 2.

8(Original). The pharmaceutical composition of claim 6, further comprising interleukin 12.

9(Original). The pharmaceutical composition of claim 6, further comprising interleukin 3.

Claims 10-18 (Cancelled)

19(Previously presented). A pharmaceutical composition, comprising (i) an interferon- $\gamma$  inducing polypeptide having the amino acid sequence of SEQ ID NO:6, where amino acid

residue 73, as represented by Xaa, is Ile or Thr, or a fragment thereof, and having the following physicochemical properties:

(1) molecular weight

18,500  $\pm$  3,000 daltons on sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE);

(2) isoelectric point (pI)

4.9  $\pm$  1.0 on chromatofocusing;

(3) biological activity

inducing interferon- $\gamma$  production by human immunocompetent cells;

(4) acute toxicity

having an LD<sub>50</sub> of at least about one mg/kg when tested in mice; and

(5) assay

being detected with a monoclonal antibody which binds to the interferon- $\gamma$  inducing polypeptide having an amino acid sequence of SEQ ID NO:6;

(ii) a pharmaceutically acceptable carrier; and

(iii) may optionally comprise one or more compounds selected from the group consisting of an adjuvant excipient, diluent, stabilizer, and a second biologically active compound.

Claims 20-94 (Cancelled).